Developing an objective marker to optimize patient selection and predict survival benefit in early-phase cancer trials-Reference-Cited by-同舟云学术

Developing an objective marker to optimize patient selection and predict survival benefit in early-phase cancer trials

Published:2013-10-08 Issue:2 Volume:120 Page:262-270
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Stavraka Chara¹,Pinato David J.¹,Turnbull Samantha J.²,Flynn Michael J.²,Forster Martin D.³,O'Cathail Sean M.⁴,Babar Sayed⁵,Seckl Michael J.⁴,Kristeleit Rebecca S.³,Blagden Sarah P.⁴

Affiliation:

1. Department of Experimental Medicine; Imperial College London; Hammersmith Hospital; London United Kingdom

2. University College London Clinical Research Facility; University College London Hospital; London United Kingdom

3. University College London Cancer Institute; University College London; London United Kingdom

4. Department of Medical Oncology; Imperial College London; Hammersmith Campus; London United Kingdom

5. Imaging Department; Hammersmith Hospital; Imperial College Healthcare NHS Trust; London United Kingdom

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference32 articles.

1. Phase I clinical trial design in cancer drug development;Eisenhauer;J Clin Oncol,2000

2. Risks and benefits of phase 1 oncology trials, 1991 through 2002;Horstmann;N Engl J Med,2005

3. Identification of factors limiting patient recruitment into phase I trials: a study from the Royal Marsden Hospital;Karavasilis;Eur J Cancer,2008

4. Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret Hospital;Ho;BMC Cancer,2006

5. 90-Days mortality rate in patients treated within the context of a phase-I trial: how should we identify patients who should not go on trial?;Arkenau;Eur J Cancer,2008

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Hammersmith Score Optimises Patient Selection and Predicts for Overall Survival in Early-Phase Cancer Trial Participants Independent of Tumour Burden;Chemotherapy;2024-04-27

2. Validation and comparison of prognostic scoring systems in patients with head and neck squamous cell carcinoma treated with nivolumab;Japanese Journal of Clinical Oncology;2024-03-30

3. Construction and Validation of a Serum Albumin-to-Alkaline Phosphatase Ratio-Based Nomogram for Predicting Pathological Complete Response in Breast Cancer;Frontiers in Oncology;2021-10-08

4. Clinical Predictors of Early Trial Discontinuation for Patients Participating in Phase I Clinical Trials in Oncology;Cancers;2021-05-11

5. A Predictive Score of Antitumour Activity of Novel Agents in Cancer Patients Treated in Early Phase Studies;Oncology;2021